Searchable abstracts of presentations at key conferences in endocrinology

ea0038p153 | Neoplasia, cancer and late effects | SFEBES2015

Novel targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma

Young Karen , Alusi Ghassan , Korbonits Marta

Background: Olfactory neuroblastoma (ONB), a neuroendocrine nasal tumour, exhibits a range of phenotypes from indolent to very aggressive. Even early disease is associated with high (60%) recurrence rates, while advanced disease has 1.5y disease-free and 2.5y overall mean survival. Medical treatments against primary and recurrent disease as well as prognostic biomarkers are urgently required. The few studies available suggest that mTOR/MAPK and Sonic Hedgehog signalling has a ...

ea0044p165 | Neuroendocrinology and pituitary | SFEBES2016

Olfactory neuroblastoma: a multi centre clinical and pathological review

Young Karen , Orban Nara , Clarke Peter , Sandison Ann , Gilkes Catherine , Alusi Ghassan , Korbonits Marta

Olfactory neuroblastoma (ONB) is a rare neuroendocrine tumour arising within the sino-nasal cavity. It occurs world wide, affecting both sexes, all ages and all races with no underlying predilection having yet been identified. ONB exhibits a range of phenotypes from indolent to very aggressive, and up to 5% cases are associated with ectopic hormone secretion. Despite current gold-standard treatment of surgical resection (either endoscopic or craniofacial resection) followed by...

ea0030p2 | (1) | BSPED2012

Outcome of endoscopic transsphenoidal pituitary surgery in four paediatric Cushing's disease patients: a new therapeutic approach

Storr Helen L , Drake William M , Akker Scott A , Monson John P , Savage Martin O , Alusi Ghassan , Sabin H Ian

Selective transsphenoidal adenomectomy remains the accepted first line treatment for Cushing’s disease (CD), until recently by microscopic (sublabial) transsphenoidal pituitary surgery. Endonasal transsphenoidal endoscopic surgery is emerging as a novel, less invasive treatment for pituitary adenomas with lower postoperative complications and morbidity. The safety of endoscopic surgery has been extensively reviewed in adult patients and is now considered best practice for...

ea0015p373 | Thyroid | SFEBES2008

An unusual cause of a thyroid mass

Thomas Julia , Norton Andrew , Calaminici Maria , Plowman P Nicholas , Richards Polly , Alusi Ghassan , Montoto Silvia , Akker Scott

A 24-year-old woman presented with stridor resulting from a large, firm, anterior neck mass. At age six she had been treated for acute lymphoblastic leukaemia (ALL) with vincristine, prednisolone, daunorubicin, asparaginase, prophylactic cranial radiotherapy and intrathecal methotrexate. She also had primary hypothyroidism with strongly positive thyroid peroxidase antibodies.The mass had been gradually enlarging for 6 months, causing exertional breathles...

ea0028p236 | Pituitary | SFEBES2012

Evaluation of the expression of vesicular protein (SNARE) isoforms in human pituitary adenomas

Garcia Edwin , Trivellin Giampaolo , Michael Powell , Grieve Joan , Sabin Ian , Alusi Ghassan , Louis Pobereskin , Shariati Babak , Roncaroli Federico , Mendoza Nigel , Grossman Ashley , Harper Elaine , Korbonits Marta

Background: Botulinum neurotoxin inhibits muscle function by interfering with neurotransmitter release from secretory vesicles. The mechanism underlying this effect involves cleavage of SNARE proteins which are required for vesicle docking at the plasma membrane. The ability of botulinum neurotoxin serotypes to cleave SNARE proteins and inhibit secretion is being exploited for therapeutic purposes by Syntaxin Ltd with their ‘targeted secretion inhibitor technology’ (...